Management of triple negative breast cancer

Catherine Oakman, Giuseppe Viale, Angelo Di Leo

Research output: Contribution to journalArticlepeer-review


Triple negative breast cancer (TNBC) accounts for approximately 15% of breast cancer cases. TNBC is an immunohistochemically defined subtype, with significant diversity within the subtype. Generally TNBC occurs in younger women and is marked by high rates of relapse, visceral and CNS metastases, and early death. Current therapy fails to curtail the innate aggressive behaviour of TNBC in the majority of patients. The poor prognosis coupled with a lack of targeted use of therapies is reflected in the high mortality. In a minority of patients with highly chemosensitive disease, no robust clinical evidence exists to guide use of current cytotoxics. Critical to optimal future management are accurate identification of truly triple negative disease and adequately powered prospective TNBC trials to establish treatment efficacy and define predictive biomarkers.

Original languageEnglish
Pages (from-to)312-321
Number of pages10
Issue number5
Publication statusPublished - Oct 2010


  • Breast cancer
  • Immunohistochemistry
  • Predictive biomarker
  • Treatment
  • Triple negative

ASJC Scopus subject areas

  • Surgery


Dive into the research topics of 'Management of triple negative breast cancer'. Together they form a unique fingerprint.

Cite this